Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

Cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity are two major CAR T related toxicities. With the interventions of Tocilizumab and steroids, many patients can recover from severe CRS. However, some patients are refractory to steroids and develop life‐threatening cons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Pan, Jing, Deng, Biping, Ling, Zhuojun, Song, Weiliang, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Tan, Yue
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812291/
https://ncbi.nlm.nih.gov/pubmed/33314568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16176
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados